<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the effects of intensive insulin therapy alone or with added <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on renal salt/water balance and body fluid compartment shifts in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A total of 25 insulin-treated, <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomized to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 45 mg (n = 12) or placebo (n = 13) and treated intensively for 12-16 weeks to achieve equivalent glycaemic control </plain></SENT>
<SENT sid="2" pm="."><plain>We measured total body water (TBW) and extracellular/intracellular fluid by bioimpedance analysis; plasma/RBC volume with I(131)albumin; <z:chebi fb="199" ids="26708">sodium</z:chebi> handling by fractional excretion of <z:chebi fb="199" ids="26708">sodium</z:chebi>/<z:chebi fb="32" ids="30145">lithium</z:chebi> (FeNa/FeLi) and other renal/hormonal parameters </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Intensification of insulin therapy and the addition of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> significantly improved glycaemia (HbA1C 7.8-7.2% and 7.6-7.1%) and <z:hpo ids='HP_0004324'>increased body weight</z:hpo> (1.7 and 4.9 kg) respectively </plain></SENT>
<SENT sid="4" pm="."><plain>TBW increased 1.7 l with insulin alone (65% intracellular) and 1.6 l with added <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (75% extracellular) (p = 0.06 and 0.09 respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Plasma volume increased 0.2 +/- 0.1 l with insulin alone (p = 0.05) and 0.4 +/- 0.1 l with added <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Extravascular, extracellular (interstitial) fluid increased significantly and more with added <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (0.8 +/- 0.2 l, p &lt; 0.01) than with insulin alone (0.4 +/- 0.2 l, p = ns) </plain></SENT>
<SENT sid="7" pm="."><plain>At steady-state, FeLi (marker of proximal-tubular <z:chebi fb="199" ids="26708">sodium</z:chebi> delivery to the distal nephron) increased significantly with added <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (12.4 +/- 1.3 to 18.0 +/- 3.2%) vs. no significant change with insulin alone (15.4 +/- 1.2 to 14.5 +/- 2.3%) </plain></SENT>
<SENT sid="8" pm="."><plain>There were no significant changes in the other parameters </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: In intensively insulin-treated <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic patients, at equivalent glycaemic control, the addition of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> causes greater <z:mp ids='MP_0005456'>weight gain</z:mp>, but a similar increase in body water that is mainly extracellular and interstitial compared with intracellular increase with insulin therapy alone </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> also increases the filtered load of <z:chebi fb="199" ids="26708">sodium</z:chebi> reabsorbed at the distal nephron with no net change in FeNa </plain></SENT>
</text></document>